Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review

Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Cutaneous Medicine and Surgery 2018-11, Vol.22 (6), p.591-601
Hauptverfasser: Zhou, Linghong Linda, Georgakopoulos, Jorge R., Ighani, Arvin, Yeung, Jensen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 601
container_issue 6
container_start_page 591
container_title Journal of Cutaneous Medicine and Surgery
container_volume 22
creator Zhou, Linghong Linda
Georgakopoulos, Jorge R.
Ighani, Arvin
Yeung, Jensen
description Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.
doi_str_mv 10.1177/1203475418773358
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2032797001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1203475418773358</sage_id><sourcerecordid>2032797001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRrFbvniTgxUt0J5vNJt5K0SpULFrxGHaTiabko-5ulPrXuyVVoeBplpnfe7PzCDkBegEgxCUElIWChxALwRiPd8gBRMB9ATTZdW839tfzATk0ZkEpBeDhPhkEiaAiEckBeXlaGYt1mXn3bdPaN9RyufLmGqWtsbHGK1rtTbBx_ar8wtybdcZ2ldTezLS6lKY0V97I612kdT6P-FHi5xHZK2Rl8HhTh-T55no-vvWnD5O78WjqZyED6-dQZApYoliRB1zmoAIIFYCitFBxHoaIQR4xyZRE4HEeZyqBIuLCCWXMORuS8953qdv3Do1N69JkWFWywbYzqUsgcJe6yx16toUu2k437ndpAFxEEMZJ7CjaU5lujdFYpEtd1lKvUqDpOvR0O3QnOd0Yd6rG_Ffwk7ID_B4w8hX_tv5r-A2Mk4my</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157614898</pqid></control><display><type>article</type><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</creator><creatorcontrib>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</creatorcontrib><description>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</description><identifier>ISSN: 1203-4754</identifier><identifier>EISSN: 1615-7109</identifier><identifier>DOI: 10.1177/1203475418773358</identifier><identifier>PMID: 29707979</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Drug therapy ; Evidence ; Female ; Humans ; Male ; Middle Aged ; Psoriasis ; Psoriasis - drug therapy ; Skin diseases ; Systematic review</subject><ispartof>Journal of Cutaneous Medicine and Surgery, 2018-11, Vol.22 (6), p.591-601</ispartof><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</citedby><cites>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</cites><orcidid>0000-0002-6844-2724</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1203475418773358$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1203475418773358$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,315,782,786,794,21826,27929,27931,27932,43628,43629</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29707979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Linghong Linda</creatorcontrib><creatorcontrib>Georgakopoulos, Jorge R.</creatorcontrib><creatorcontrib>Ighani, Arvin</creatorcontrib><creatorcontrib>Yeung, Jensen</creatorcontrib><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><title>Journal of Cutaneous Medicine and Surgery</title><addtitle>J Cutan Med Surg</addtitle><description>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</description><subject>Adult</subject><subject>Drug therapy</subject><subject>Evidence</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Skin diseases</subject><subject>Systematic review</subject><issn>1203-4754</issn><issn>1615-7109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1Lw0AQxRdRrFbvniTgxUt0J5vNJt5K0SpULFrxGHaTiabko-5ulPrXuyVVoeBplpnfe7PzCDkBegEgxCUElIWChxALwRiPd8gBRMB9ATTZdW839tfzATk0ZkEpBeDhPhkEiaAiEckBeXlaGYt1mXn3bdPaN9RyufLmGqWtsbHGK1rtTbBx_ar8wtybdcZ2ldTezLS6lKY0V97I612kdT6P-FHi5xHZK2Rl8HhTh-T55no-vvWnD5O78WjqZyED6-dQZApYoliRB1zmoAIIFYCitFBxHoaIQR4xyZRE4HEeZyqBIuLCCWXMORuS8953qdv3Do1N69JkWFWywbYzqUsgcJe6yx16toUu2k437ndpAFxEEMZJ7CjaU5lujdFYpEtd1lKvUqDpOvR0O3QnOd0Yd6rG_Ffwk7ID_B4w8hX_tv5r-A2Mk4my</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Zhou, Linghong Linda</creator><creator>Georgakopoulos, Jorge R.</creator><creator>Ighani, Arvin</creator><creator>Yeung, Jensen</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6844-2724</orcidid></search><sort><creationdate>20181101</creationdate><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><author>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Drug therapy</topic><topic>Evidence</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Skin diseases</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Linghong Linda</creatorcontrib><creatorcontrib>Georgakopoulos, Jorge R.</creatorcontrib><creatorcontrib>Ighani, Arvin</creatorcontrib><creatorcontrib>Yeung, Jensen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Linghong Linda</au><au>Georgakopoulos, Jorge R.</au><au>Ighani, Arvin</au><au>Yeung, Jensen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</atitle><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle><addtitle>J Cutan Med Surg</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>22</volume><issue>6</issue><spage>591</spage><epage>601</epage><pages>591-601</pages><issn>1203-4754</issn><eissn>1615-7109</eissn><abstract>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>29707979</pmid><doi>10.1177/1203475418773358</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6844-2724</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1203-4754
ispartof Journal of Cutaneous Medicine and Surgery, 2018-11, Vol.22 (6), p.591-601
issn 1203-4754
1615-7109
language eng
recordid cdi_proquest_miscellaneous_2032797001
source Access via SAGE; MEDLINE
subjects Adult
Drug therapy
Evidence
Female
Humans
Male
Middle Aged
Psoriasis
Psoriasis - drug therapy
Skin diseases
Systematic review
title Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T16%3A29%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20Monotherapy%20Treatments%20for%20Generalized%20Pustular%20Psoriasis:%20A%20Systematic%20Review&rft.jtitle=Journal%20of%20Cutaneous%20Medicine%20and%20Surgery&rft.au=Zhou,%20Linghong%20Linda&rft.date=2018-11-01&rft.volume=22&rft.issue=6&rft.spage=591&rft.epage=601&rft.pages=591-601&rft.issn=1203-4754&rft.eissn=1615-7109&rft_id=info:doi/10.1177/1203475418773358&rft_dat=%3Cproquest_cross%3E2032797001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157614898&rft_id=info:pmid/29707979&rft_sage_id=10.1177_1203475418773358&rfr_iscdi=true